DexCom Inc.
Moat Score — DexCom Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Dexcom's CGM sensor technology is protected by patents and years of FDA clearance work, and its G6/G7 platforms carry a strong reputation for accuracy among clinicians and patients that is difficult for a new entrant to establish quickly. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Dexcom is not the low-cost producer in its category — rival Abbott's FreeStyle Libre is generally priced lower and has a larger global user base, leaving Dexcom competing more on accuracy and features than on cost. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Reimbursement is negotiated with insurers and government payers rather than set freely by Dexcom, and Abbott's lower-cost Libre franchise puts ongoing competitive pressure on price, limiting Dexcom's pricing flexibility. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | Deep data-integration partnerships with insulin pump makers (Tandem, Insulet) create a mild ecosystem benefit as more devices and apps build around Dexcom's data feed, though this falls well short of a true multi-sided network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Patients and clinicians build therapy routines and automated insulin delivery configurations around a specific CGM, and switching disrupts established pump integrations and prescriber familiarity, making established users unlikely to change sensors. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | CGM is effectively a two-to-three player global market (Dexcom, Abbott, Medtronic) given the R&D, manufacturing, and regulatory scale required to compete, though Abbott's larger scale and lower price point show the market is not fully efficient-scale-protected for Dexcom specifically. |